Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/02/2012WO2012015325A1 Stabilized immune correction drug viferon-forte for the treatment of infectious inflammatory diseases
02/02/2012WO2012015323A1 Use of a mixture of probiotic bacteria in a mixture with short - chain fatty acids
02/02/2012WO2012015255A2 Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
02/02/2012WO2012015249A2 Method for screening diabetes treating agent
02/02/2012WO2012015168A2 Pharmaceutical composition comprising rosuvastatin or a pharmaceutically acceptable salt thereof
02/02/2012WO2012015157A1 Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same
02/02/2012WO2012015043A1 Liquid pharmaceutical composition
02/02/2012WO2012015027A1 Therapeutic agent or prophylactic agent for neuropathic pain
02/02/2012WO2012015024A1 Ethinyl-pyrazole derivative
02/02/2012WO2012014994A1 Naphthalene derivative
02/02/2012WO2012014993A1 Agent for increasing translation initiation factor or translation elongation factor, and use thereof for medical purposes
02/02/2012WO2012014963A1 Condensed ring pyridine compound
02/02/2012WO2012014945A1 Novel nucleic acid having adjuvant activity and use thereof
02/02/2012WO2012014936A1 Cancer stem cell differentiation inducer
02/02/2012WO2012014910A1 P2x4 receptor antagonist
02/02/2012WO2012014903A1 Fat-containing composition and oral formulation containing same
02/02/2012WO2012014890A1 NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO c-Met AND USE THEREOF
02/02/2012WO2012014848A1 Flavoniod-derived hes-1 promoter inhibitor
02/02/2012WO2012014805A1 Nitric oxide generation regulator
02/02/2012WO2012014746A1 Α-lipoic acid complex
02/02/2012WO2012014699A1 Therapeutic agent for neurological diseases
02/02/2012WO2012014630A1 Astaxanthin-containing aqueous composition, cosmetic preparation, and method for suppressing degradation of astaxanthin
02/02/2012WO2012014524A1 Sugar metabolism improving composition, and pharmaceutical preparation containing said composition
02/02/2012WO2012014238A1 Composition for the treatment and prevention of herpes simplex labialis
02/02/2012WO2012014221A1 Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
02/02/2012WO2012014218A1 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
02/02/2012WO2012014165A1 A method of managing broncho-constrictive condition
02/02/2012WO2012014149A1 N-methylformamide solvate of dasatinib
02/02/2012WO2012014127A1 5-lipoxygenase inhibitors
02/02/2012WO2012014114A1 Matrix metalloproteinase inhibitors
02/02/2012WO2012014109A1 Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
02/02/2012WO2012014085A2 Uses of cimiracemate and related compounds for treating inflammation and modulating immune responses
02/02/2012WO2012014052A2 Novel coated extended release pharmaceutical compositions containing paliperidone
02/02/2012WO2012014016A1 Method of treating animal drinking water with interval dosing of a biocide
02/02/2012WO2012014012A1 Method for producing tablets that dissolve rapidly in the mouth and that include form i of olanzapine, resulting tablets and use thereof in the treatment of schizophrenia
02/02/2012WO2012013990A2 Medication for curing the disease of psoriasis
02/02/2012WO2012013975A1 Nutritional compositions
02/02/2012WO2012013884A1 Compounds for the treatment/prevention of ocular inflammatory diseases
02/02/2012WO2012013848A1 Difluorobenzyl ethanolamine derivatives with antimicrobial activity
02/02/2012WO2012013821A1 Inhibition of dicer function for treatment of cancer
02/02/2012WO2012013816A1 Compounds and methods for treating neoplasia
02/02/2012WO2012013791A1 Compositions for treating heartworm infestation
02/02/2012WO2012013784A1 Regulation of glypican 4 activity to modulate the fate of stem cells and uses thereof
02/02/2012WO2012013750A1 Use of dronedarone for the preparation of a medicament for the hospitalization burden in patient with atrial fibrillation
02/02/2012WO2012013736A1 Preservative-free composition for topical use including hyaluronic acid
02/02/2012WO2012013728A1 Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
02/02/2012WO2012013727A1 Cyclopropylamine derivatives useful as lsd1 inhibitors
02/02/2012WO2012013725A1 Vinylogous chalcone derivatives and their medical use
02/02/2012WO2012013716A1 Bicyclic acetyl-coa carboxylase inhibitors
02/02/2012WO2012013691A1 Multitarget substituted biphenyl diol derivatives
02/02/2012WO2012013671A1 Processes for the production of 14 - oxygenated morphinan - 6 - ones
02/02/2012WO2012013670A1 Process for the esterification of hyaluronic acid with hydrophobic organic compounds
02/02/2012WO2012013643A1 Hetero-bicyclic derivatives as hcv inhibitors
02/02/2012WO2012013595A1 Three-phase controlled-release tablet comprising melatonin and process of preparation
02/02/2012WO2012013567A1 Pharmaceutical composition for treatment of respiratory and inflammatory diseases
02/02/2012WO2012013566A1 Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
02/02/2012WO2012013557A1 Isoxazolo-quinazolines as modulators of protein kinase activity
02/02/2012WO2012013343A1 Cis-tetrahydrospiro(cyclohexane-1,1'-pyrido[3,4-b]indol)-4-amine derivatives
02/02/2012WO2012013282A1 Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
02/02/2012WO2012013147A1 Acenaphtho heterocyclic compound and application thereof
02/02/2012WO2012013118A1 Carvedilol sulfate crystals, preparation method thereof, and pharmaceutical use thereof
02/02/2012WO2012013117A1 Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof
02/02/2012WO2012013116A1 Pharmaceutical composition of temozolomide comprising amino acid stabilizer and preparation method thereof
02/02/2012WO2012013088A1 Dronedarone solid dispersion and preparation method thereof
02/02/2012WO2012013020A1 Anti-fatigue composition, formulation and use thereof
02/02/2012WO2012013016A1 Curcumalactone derivatives with antitumor activity and preparation process thereof
02/02/2012WO2012013012A1 Benzo-azacyclic hydroxyethylamine compound, preparation method and uses thereof
02/02/2012WO2012012941A1 Bcl-2 family protein inhibitors, their cyclodextrin inclusion compounds, complexes, and uses in manufacture of bcl-2 family protein inhibitors thereof
02/02/2012WO2012012902A1 S-adenosylmethionine formulations with enhanced bioavailability
02/02/2012WO2012012891A1 Compounds, compositions and methods for treatment of arthritis
02/02/2012WO2012012890A1 Compounds, compositions and methods for treatment of arthritis
02/02/2012WO2012012887A1 Resveratrol extraction from gnetum africanum
02/02/2012WO2012012886A1 Compounds and extracts from gnetum africanum and anti-inflammatory activity related thereto
02/02/2012WO2012012870A1 Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
02/02/2012WO2011156901A3 Compounds, compositions and methods for treatment of multiple sclerosis
02/02/2012WO2011156563A3 Oral iron deficiency therapy
02/02/2012WO2011156557A3 Compounds active at the neurotensin receptor
02/02/2012WO2011155689A3 Method for preparing an intermediate of pitavastatin or of the salt thereof
02/02/2012WO2011151436A3 Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists
02/02/2012WO2011149354A8 Mirnas involved in the blood brain barrier function
02/02/2012WO2011145914A4 Lidocaine as a transformer and producer of transformed complexes of drugs delivered in nano-dosages using injection implants as prolonged release devices
02/02/2012WO2011144746A3 Liquid nasal spray containing low-dose naltrexone
02/02/2012WO2011144725A3 Novel methods for preventing or treating diabetes
02/02/2012WO2011142652A8 Composition for reducing absorption of dietary fat
02/02/2012WO2011135580A3 Pharmaceutical compositions of sirolimus
02/02/2012WO2011134937A3 Pharmaceutical emulsion compositions comprising progestogen
02/02/2012WO2011133826A3 Method for treating pancreatic cancer
02/02/2012WO2011133480A3 Method of treating gastric cancer
02/02/2012WO2011133479A3 Combination therapy with a proteasome inhibitor and a gallium complex
02/02/2012WO2011130419A3 Broad spectrum antiviral and antiparasitic agents
02/02/2012WO2011129627A3 Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration
02/02/2012WO2011129579A3 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
02/02/2012WO2011129549A3 Anticancer drug delivery system using ph-sensitive metal nanoparticles
02/02/2012WO2011127388A3 Inverse agonists and neutral antagonists for the tsh receptor
02/02/2012WO2011127333A3 Compounds for treating disease, for administering, and for pharmaceutical compositions
02/02/2012WO2011127048A3 NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
02/02/2012WO2011126327A3 Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
02/02/2012WO2011123536A8 Polycyclic tetracycline compounds
02/02/2012WO2011122899A3 Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis
02/02/2012WO2011109732A3 Reverse thermal gels and uses therefor
1 ... 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 ... 7860